Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iron Sucrose Staining for Lung Segmentectomy
NCT03516500Phase 2
Key facts
- Status
- Completed
- Start
- May 2018
- Primary completion
- Jan 2021
- Countries
- 1
- Sponsor
- Ruijin Hospital
- Modality
- Small Molecules
- Drugs
- iron sucrose
- Conditions
- lung neoplasm
01
Overview
Phase 2, open-label, single-arm trial of iron sucrose in lung neoplasm, sponsored by Ruijin Hospital. Primary endpoint: Incidence of treatment-related grade 3-5 adverse events. Started May 2018; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Iron Sucrose injection group
Patients receiving Iron Sucrose injection for lung segment staining
03
Endpoints
Primary
Incidence of treatment-related grade 3-5 adverse events
Secondary
Surgical margin
Beyond the preview
Go deeper on NCT03516500.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03516500.